Status:

RECRUITING

Leiden Thrombosis Recurrence Risk Prevention

Lead Sponsor:

Leiden University Medical Center

Conditions:

Venous Thromboembolism

Venous Thromboses

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The goal of this clinical trial is to evaluate tailored duration of long-term anticoagulant treatment after a first venous thromboembolism based on individualized risk assessments of recurrent VTE and...

Detailed Description

Background: Patients with a first venous thromboembolism (VTE) are at risk of recurrence. A recurrent VTE can be prevented by prolonged anticoagulant therapy, but this may come at the cost of major bl...

Eligibility Criteria

Inclusion

  • Provision of informed consent prior to any study specific procedures.
  • Be diagnosed with a first confirmed symptomatic deep vein thrombosis (including distal vein thrombosis, in Dutch: 'kuitvenetrombose') or pulmonary embolism with an indication for treatment with anticoagulant therapy for at least 3 months as prescribed by their treating physician.
  • Be aged 18 years or above.

Exclusion

  • Patients with active cancer (i.e. cancer diagnosis within six months before VTE (excluding basal-cell or squamous-cell carcinoma of the skin), recently recurrent or progressive cancer or any cancer that required anti-cancer treatment within six months before the venous thromboembolism was diagnosed) or antiphospholipid syndrome
  • Patients who need to continue anticoagulant treatment for another indication (e.g. atrial fibrillation).
  • Patients with a strong indication for long-term antiplatelet therapy despite oral anticoagulation (e.g. those with recent STEMI)
  • Patients with COVID-19 associated VTE (hospital admission because of COVID-19 \<3 months before the VTE) or vaccine-induced immune thrombotic thrombocytopenia (VITT)
  • Patients in whom the risk of bleeding is deemed extremely high by the treating physician, necessitating discontinuation of anticoagulant treatment for the first VTE after the initial 3 months or even during the initial 3 months.

Key Trial Info

Start Date :

June 18 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2027

Estimated Enrollment :

608 Patients enrolled

Trial Details

Trial ID

NCT06087952

Start Date

June 18 2021

End Date

June 1 2027

Last Update

March 7 2025

Active Locations (19)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (19 locations)

1

Leiden University Medical Center

Leiden, South Holland, Netherlands, 2333 ZA

2

Amsterdam Medical Center, location AMC

Amsterdam, Netherlands

3

Wilhelmina Ziekenhuis

Assen, Netherlands

4

Rode Kruis Ziekenhuis

Beverwijk, Netherlands